From platinum compounds to targeted therapies in advanced thoracic malignancies

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 477-482

  Jakopovic, Marko ^a   Thomas, Anish ^b   Lopez Chavez, Ariel ^c  

^a KBC Zagreb   (Croatia)

^b NATIONAL CANCER INSTITUTE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Advanced thoracic malignancies; Platinum based chemotherapy; Review; Targeted therapy

Indexed keywords

PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; HUMAN; MEDICAL RESEARCH; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SMALL CELL LUNG CANCER; THORAX CANCER; ADVANCED THORACIC MALIGNANCIES; ANIMAL; CHEMISTRY; ENZYMOLOGY; PLATINUM-BASED CHEMOTHERAPY; PROGNOSIS; REVIEW; TARGETED THERAPY; THORAX TUMOR;

ADVANCED THORACIC MALIGNANCIES; PLATINUM-BASED CHEMOTHERAPY; REVIEW; TARGETED THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; THORACIC NEOPLASMS;

EID: 84897025995     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (55)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Khuder SA: Effect of cigarette smoking on major histological types of lung cancer: A meta-analysis. Lung Cancer 31: 139-148, 2001.
3. Vineis P, Airoldi L, Veglia F, Olgiati L, Pastorelli R, Autrup H, Dunning A, Garte S, Gormally E, Hainaut P, Malaveille C, Matullo G, Peluso M, Overvad K, Tjonneland A, Clavel-Chapelon F, Boeing H, Krogh V, Palli D, Panico S, Tumino R, Bueno-De-Mesquita B, Peeters P, Berglund G, Hallmans G, Saracci R and Riboli E: Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 330: 277, 2005.
4. Tardon A, Lee WJ, Delgado-Rodriguez M, Dosemeci M, Albanes D, Hoover R and Blair A: Leisure-time physical activity and lung cancer: A meta-analysis. Cancer Causes Control 16: 389-397, 2005.
5. Lee IM: Physical activity and cancer prevention-data from epidemiologic studies. Med Sci Sports Exerc 35: 1823-1827, 2003.
6. Engels EA: Epidemiology of thymoma and associated malignancies. J Thoracic Oncol 5: S260-S265, 2010.
7. Chen PC, Pan CC, Yang AH, Wang LS and Chiang H: Detection of Epstein-Barr virus genome within thymic epithelial tumours in Taiwanese patients by nested PCR, PCR in situ hybridization, and RNA in situ hybridization. J Pathol 197: 684-688, 2002.
8. Manca N, Perandin F, De Simone N, Giannini F, Bonifati D and Angelini C: Detection of HTLV-I tax-rex and pol gene sequences of thymus gland in a large group of patients with myasthenia gravis. J Acquir Immune Defic Syndr 29: 300-306, 2002.
9. Jett JR and Carr LL: Targeted therapy for non-small cell lung cancer. Am J Respir Crit Care Med 188: 907-912, 2013.
10. Woodcock TM, Blumenreich MS, Richman SP, Kubota TT, Gentile PS and Allegra JC: Combination chemotherapy with cis-diamminedichloroplatinum and vinblastine in advanced nonsmall cell lung cancer. J Clin Oncol 1: 247-250, 1983.
11. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002.
12. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP and Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
13. Sandler A, Yi J, Dahlberg S, Kolb MM, Wang L, Hambleton J, Schiller J and Johnson DH: Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 5: 1416-1423, 2010.
14. Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE and Green MR: Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and leukemia group B trial 9732. J Clin Oncol 23: 3752-3759, 2005.
15. Bonomi PD, Finkelstein D, Aisner S and Ettinger D: EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol 16: 342-345, 1993.
16. Highley MS, Underhill CR, Parnis FX, Karapetis C, Rankin E, Dussek J, Bryant B, Rowland C, Hodson N, Hughes J and Harper PG: Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 17: 2737-2744, 1999.
17. Loehrer PJ, Sr., Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D and Blum R: Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 12: 1164-1168, 1994.
18. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T and van Zandwijk N: Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14: 814-820, 1996.
19. Loehrer PJ Sr., Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR Jr., Livingston R and Johnson DH: Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: An intergroup trial. Cancer 91: 2010-2015, 2001.
20. Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH and Loehrer PJ, Sr: Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29: 2060-2065, 2011.
21. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia- Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sanchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ and Taron M: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967, 2009.
22. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
23. Dearden S, Stevens J, Wu YL and Blowers D: Mutation incidence and coincidence in non small-cell lung cancer: Metaanalyses by ethnicity and histology (mutMap). Ann Oncol 24: 2371-2376, 2013.
24. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA and Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
25. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S and Nukiwa T: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.
26. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K and Fukuoka M: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.
27. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW and Jo SJ: First-SIGNAL: First-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30: 1122-1128, 2012.
28. Zhou CC, Wu YL, Chen GY, Feng JF, Liu XQ, Wang CL, Zhang SC, Wang J, Zhou SW, Ren SX, Lu S, Zhang L, Hu CP, Hu CH, Luo Y, Chen L, Ye M, Huang JN, Zhi XY, Zhang YP, Xiu QY, Ma J, Zhang L and You CX: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase III study. Lancet Oncology 12: 735-742, 2011.
29. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Munoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M and Paz-Ares L: Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): A multicentre, open-label, randomised phase III trial. Lancet Oncology 13: 239-246, 2012.
30. Sequist L, Schuler M, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Massey D, Zazulina V, Shahidi M and Yang J: LUX-Lung 3: A randomized, open-label, phase III study of afatinib vs. pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations (subgroup analysis). J Thorac Oncol 7: S203-S207, 2012.
31. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. V: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.. J Clin Oncol 31: 3327-3334, 2013.
32. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara SI, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y and Mano H: Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature 448: 561-566, 2007.
33. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M and Janne PA: EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275-4283, 2008.
34. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA and Dias-Santagata D: Implementing multiplexed genotyping of non-small cell lung cancers into routine clinical practice. Ann Oncol 22: 2616-2624, 2011.
35. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ and Iafrate AJ: Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: 4247-4253, 2009.
36. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SHI, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan WW, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW and Iafrate AJ: Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. New Engl J Med 363: 1693-1703, 2010.
37. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SHI, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Janne PA, Costa DB, Shapiro GI, LoRusso P, Ruffner K, Stephenson P, Tang YY, Wilner K, Clark JW and Shaw AT: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase I study. Lancet Oncology 13: 1011-1019, 2012.
38. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD and Janne PA: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. New Engl J Med 368: 2385-2394, 2013.
39. Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, Spiro S, James L, Ali K, Jitlal M and Hackshaw AL: Antiangiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: A randomized, doubleblind, placebo-controlled trial. J Natl Cancer Inst 101: 1049-1057, 2009.
40. van Meerbeeck JP, Fennell DA and De Ruysscher DKM: Small-cell lung cancer. Lancet 378: 1741-1755, 2011.
41. Rajan A and Giaccone G: Targeted therapy for advanced thymic tumors. J Thorac Oncol 5: S361-S364, 2010.
42. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, Lothaire P, Meert AP, Noel S, Lafitte JJ and Sculier JP: The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with metaanalysis. Br J Cancer 92: 131-139, 2005.
43. Riely GJ, Brahmer JR, Planchard D, Crino L, Doebele RC, Lopez LAM, Gettinger SN, Schumann C, Li XY, Atkins BM, Ebbinghaus S and Rosell R: A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. J Clin Oncol 30: A7531, 2012.
44. Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I and Crino L: Selumetinib plus docetaxel for KRAS-mutant advanced non-small cell lung cancer: A randomised, multicentre, placebo-controlled, phase II study. Lancet Oncology 14: 38-47, 2013.
45. Wang SZE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang SC, Carpenter G, Gazdar AF, Muthuswamy SK and Arteaga CL: HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer cell 10: 25-38, 2006.
46. De Greve J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, Everaert H, Umelo I, In't Veld P and Schallier D: Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 76: 123-127, 2012.
47. Ross HJ, Blumenschein GR, Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie M, Hassani H, Allen KE, Leopold L, Zaks TZ and Shepherd FA: Randomized phase ii multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 16: 1938-1949, 2010.
48. Naoki K, Chen TH, Richards WG, Sugarbaker DJ and Meyerson M: Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 62: 7001-7003, 2002.
49. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK and Ribas A: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. New Engl J Med 366: 707-714, 2012.
50. Bergethon K, Shaw AT, Ou SHI, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen HQ, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji HB, Engelman JA, Mino-Kenudson M, Pao W and Iafrate AJ: ROS1 Rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30: 863-870, 2012.
51. Strobel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, Strauss L, Sauer C, Mayer F, Hohenberger P and Marx A: Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience. Br J Cancer 103: 196-200, 2010.
52. Li XF, Chen Q, Huang WX and Ye YB: Response to sorafenib in cisplatin-resistant thymic carcinoma: A case report. Med Oncol 26: 157-160, 2009.
53. Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, Trepel J, Lee MJ, Cao L, Espinoza-Delgado I, Spittler J, Loehrer PJ, Sr. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 29: 2052-2059, 2011.
54. Rajan A BA, Kelly RJ et al: Phase II study of the insulin-like growth factor-1 receptor (IGF-1R) antibody cixutumumab (C) in patients (pts) with thymoma (T) and thymic carcinoma (TC) J Clin Oncol 28: e17525, 2010.
55. Wakelee HA BM, Gubens M, Barbeau S and Loehrer PJ: A phase II study of saracatinib (AZD0530), a SRC inhibitor, administered orally daily to patients (pts) with advanced thymic malignancies (ATM). Abstract for the International Thymic Malignancy Interest Group (ITMIG) Conference; New York. May, 2010.